Positive Data On Bayer/Algeta's Alpharadin Could Accelerate Filing Timeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III trial studying the targeted radium alpha pharmaceutical in prostate cancer patients was halted early based on positive survival results.